A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
CONCLUSION: PBI-05204 did not meet its primary endpoint for OS in this study. Recent preclinical data indicate a role for PBI-05204 against glioblastoma multiforme when combined with chemotherapy and radiotherapy. A randomized phase II trial is currently being designed.
PMID: 32452588 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Roth MT, Cardin DB, Borazanci EH, Steinbach M, Picozzi VJ, Rosemury A, Wadlow RC, Newman RA, Berlin J Tags: Oncologist Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Lessons | Oral Cancer | Pancreas | Pancreatic Cancer | Radiography | Study | Toxicology